• 7 May 2018

    Genkyotex (Euronext Paris & Brussels: FR00011790542 – GKTX), a biopharmaceutical company and the leader in NOX therapies, today announced that the independent Safety Monitoring Board (SMB) for its Phase 2 trial of GKT831 for the treatment of Primary Biliary Cholangitis (PBC) held its first pre-planned data review meeting and recommended the continuation of the Company’s trial without protocol amendment. In addition, and as previously indicated, no serious adverse events, liver-related adverse events or drop outs have been reported to date. 

  • 4 May 2018

    InDex Pharmaceuticals Holding AB (publ) today announced that it has developed a novel formulation of its lead drug candidate cobitolimod for oral administration, with targeted delivery to the lower part of the gastrointestinal tract. The oral formulation of cobitolimod is a potential follow-on product to the topical formulation, which is currently being investigated in the CONDUCT study – a phase IIb dose optimisation study in moderate to severe active ulcerative colitis.

  • 24 April 2018

    With Root Canal Awareness Week just eleven days away, Sonendo®, the developer of the GentleWave® System, has achieved a significant milestone by shipping more than 50,000 GentleWave Procedure Instruments to endodontists in the United States.

  • 23 April 2018

    TopiVert Pharma Ltd (“TopiVert” or the “Company”), a clinical-stage biotechnology company developing Narrow Spectrum Kinase Inhibitors (NSKIs) as novel, locally-acting medicines for the treatment of chronic inflammatory ocular and gastrointestinal diseases, today announces that its clinical abstract “A Phase 2 randomized, double-masked, placebo-controlled study of novel narrow spectrum kinase inhibitor TOP1630 for the treatment of dry eye syndrome” has been selected for presentation at the Association for Research in Vision and Ophthalmology (ARVO) 2018 Annual Meeting taking place 29 April–03 May 2018 in Honolulu, Hawaii.

  • 12 April 2018

    Wilson Therapeutics AB (publ), announced today that preliminary long-term efficacy and safety data from the ongoing extension phase of the company’s Phase 2 trial of WTX101 (bis-choline tetrathiomolybdate), an investigational first-in-class copper-protein-binding agent under investigation as a novel therapy for Wilson Disease, will be presented today during a Late Breaker poster session at The International Liver Congress™ 2018, the Annual Meeting of the European Association for the Study of the Liver (EASL), in Paris.